BioNexus Gene Lab Corp. (NASDAQ:BGLC) Short Interest Update

BioNexus Gene Lab Corp. (NASDAQ:BGLC) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totaling 27,606 shares, a drop of 31.3% from the December 15th total of 40,210 shares. Approximately 1.2% of the shares of the stock are sold short. Based on an average trading volume of 14,763 shares, the days-to-cover ratio is currently 1.9 days. Based on an average trading volume of 14,763 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.2% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNexus Gene Lab in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, BioNexus Gene Lab presently has a consensus rating of “Sell”.

BioNexus Gene Lab Stock Performance

Shares of NASDAQ BGLC opened at $3.65 on Friday. The company has a market cap of $8.60 million, a P/E ratio of -4.80 and a beta of 5.26. BioNexus Gene Lab has a 52-week low of $2.01 and a 52-week high of $15.60. The firm’s fifty day moving average is $4.27 and its two-hundred day moving average is $5.05.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.